160 related articles for article (PubMed ID: 9331008)
1. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
Heuer HJ; Schöndorfer G; Högemann AM
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
[No Abstract] [Full Text] [Related]
2. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
Andersson OK; Neldam S
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
[No Abstract] [Full Text] [Related]
3. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
Franke H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
[No Abstract] [Full Text] [Related]
4. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
5. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
Zanchetti A; Omboni S; Di Biagio C
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
[No Abstract] [Full Text] [Related]
6. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension.
Sever P; Holzgreve H
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S69-73. PubMed ID: 9331014
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of candesartan cilexetil in special patient groups.
Trenkwalder P
Blood Press Suppl; 2000; 1():27-30. PubMed ID: 11059633
[TBL] [Abstract][Full Text] [Related]
11. Reducing cardiovascular morbidity and mortality in the elderly.
Trenkwalder P
Blood Press Suppl; 2000; 1():40-3. PubMed ID: 11059636
[TBL] [Abstract][Full Text] [Related]
12. Achieving quality 24-h blood pressure control with candesartan cilexetil.
Meredith P
Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
14. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
Zannad F
Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
17. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
Association of Black Cardiologists (ABC) Candesartan Study Group
Heart Dis; 2000; 2(6):392-9. PubMed ID: 11728289
[TBL] [Abstract][Full Text] [Related]
19. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
20. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
